Literature DB >> 17881082

A 15-min premedication for 1-h paclitaxel infusion: optimizing patients' care.

Alessandra Milani, Tommaso De Pas, Cristina Noberasco, Colette McDonnell, Livio Libutti, Ivan Limardi, Claudia Zencovich, Sabrina Boselli, Monica Bianchi, Filippo de Braud.   

Abstract

BACKGROUND: Paclitaxel is a plant product highly active in numerous cancers, but anaphylactic-like hypersensitivity reactions with it have been reported in about 28% of patients receiving the drug. Thirty to sixty minutes are needed to give a standard premedication with steroids and diphenhydramine, leading to patients and nurses' discomfort and stealing time from other infusional treatments. PATIENTS AND METHODS: Eighty-nine patients with advanced NSCLC never pre-treated with taxanes, received paclitaxel followed by gemcitabine on days 1, 8, 15 q4wks. Premedication consisted of prednisone 25 mg/os on day 0 and hydrocortisone plus clorfenamina maleato given intravenous on day 1 by a 15 min infusion immediately before paclitaxel administration.
RESULTS: Hypersensitivity reactions occurred in 3/341 (0.8%) cycles. In all three cases we observed severe dyspnoea and bronchospasm, that required treatment discontinuation but one was probably due to gemcitabine and another had a protracting time after premedication.
CONCLUSIONS: A 15-min premedication infusion administered immediately before paclitaxel appeared to be highly effective in patients treated with 1h-infusion paclitaxel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17881082     DOI: 10.1016/j.lungcan.2007.08.009

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  2 in total

1.  Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis.

Authors:  Samuel Dubinsky; Deep Patel; Xiang Wang; Amirrtha Srikanthan; Terry L Ng; Corey Tsang
Journal:  Support Care Cancer       Date:  2022-02-12       Impact factor: 3.603

2.  Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center.

Authors:  Lincy S Lal; Donna L Gerber; Jason Lau; William Dana
Journal:  Support Care Cancer       Date:  2009-01-30       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.